Yissum - Research Development Company of the Hebrew University

Identifying and Optimizing Treatment for Neuropathic Pain

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Identifying and Optimizing Treatment for Neuropathic Pain
Project ID : 6-2019-9749

Yissum - Research Development Company of the Hebrew University
Yissum - Research Development Company of the Hebrew University

Description of the technology

Neuropathic pain- One of our distinctive results which we optimized recently identifies several compounds that we identified as having a potential protective role in neuropathic pain. We pursued this finding in collaboration with the Clinical Pain Innovation Lab at Haifa University, led by Dr. Treister, who is a clinical pain researcher with vast experience in analgesic research/development. We began validation of one of these compounds in a preclinical study, in which we assessed the compound’s potential analgesic effects in rats using the spared nerve injury model (SNI). The SNI involves ligating the tibial and common peroneal nerve while sparing the sural nerve. Mechanical pressure withdraw thresholds was assessed using Von Frey test, before and after inducing the nerve injury. The study included 6 study arms (n=5 rats in each), including three treatment arms, treated with 50, 100, and 200mg/kg body weight of the compound for five weeks, initiated 3 days post-ligation. Three additional study arms served as controls: (1) a shame control (non-ligated, i.e. were operated but without harming the nerves); (2) control (ligated) and (3) positive control (ligated) receiving imipramine (10mg/kg body weight), a tricyclic antidepressant that is approved for treating NP. As can be seen in Fig 2, the results are exciting: the drug shows statistically significant, dose-dependent, effects. Higher dosages demonstrated better analgesic effects than the positive control. These results prompted us to continue investigating the potential of this drug as a treatment for NP. Taken together, we believe that the overall picture is very supportive in continuation of our efforts to clinically evaluate the compounds efficacy in treating NP. About 10% of the general population experiences neuropathic pain (NP). Pain caused by damage or disease affecting the nervous system. The number of people experiencing neuropathic pain is constantly increasing due to the growing porportion of cancer and diabetes cases worldwide. Unfortunately, many patients with neuropathic pain do not respond to available treatments, therefore, investing in research and development of effective and improved drugs has huge potential both clinically and commercially.

The genetic revolution that has happened over the recent years brings new opportunities to the field of drug discovery & repositioning. Using advanced comparative genomic, and data integration, Dr. Tabach and his team have been developing a state-of-the-art AI algorithm which maps drug and food supplements useful in treating diseases and improving health conditions. To create this algorithm, we have been integrating and analyzing massive amounts of genomic data from 1,600 genomes, 14 thousand compounds, 20,000 human genes, and a comprehensive database of phenotypic data (figure 1).

Neuropathic pain- One of our distinctive results which we optimized recently identifies several compounds that we identified as having a potential protective role in neuropathic pain. We pursued this finding in collaboration with the Clinical Pain Innovation Lab at Haifa University, led by Dr. Treister, who is a clinical pain researcher with vast experience in analgesic research/development. We began validation of one of these compounds in a preclinical study, in which we assessed the compound’s potential analgesic effects in rats using the spared nerve injury model (SNI). The SNI involves ligating the tibial and common peroneal nerve while sparing the sural nerve. Mechanical pressure withdraw thresholds was assessed using Von Frey test, before and after inducing the nerve injury. The study included 6 study arms (n=5 rats in each), including three treatment arms, treated with 50, 100, and 200mg/kg body weight of the compound for five weeks, initiated 3 days post-ligation. Three additional study arms served as controls: (1) a shame control (non-ligated, i.e. were operated but without harming the nerves); (2) control (ligated) and (3) positive control (ligated) receiving imipramine (10mg/kg body weight), a tricyclic antidepressant that is approved for treating NP. As can be seen in Fig 2, the results are exciting: the drug shows statistically significant, dose-dependent, effects. Higher dosages demonstrated better analgesic effects than the positive control. These results prompted us to continue investigating the potential of this drug as a treatment for NP. Taken together, we believe that the overall picture is very supportive in continuation of our efforts to clinically evaluate the compounds efficacy in treating NP.

Therefore, we have currently started an open-label proof-of-concept study to assess the effects of the compound in patients with painful diabetic neuropathy. At this point in time, despite the limited number of participants, we have observed a significant improvement of symptoms, but it is too early to make any conclusions as the study is still ongoing. We plan to continue investigating this compound and continue investigating other candidate compounds that have been identified by our algorithm.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Yuval Tabach
HUJI, School of Medicine - IMRIC
Developmental Biology and Cancer Research

Related keywords

  • Information Processing, Information System, Workflow Management
  • IT and Telematics Applications
  • Multimedia
  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Computers
  • Computer Graphics Related
  • Specialised Turnkey Systems
  • Scanning Related
  • Peripherals
  • Computer Services
  • Computer Software Market
  • Other Computer Related
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • Life Science & Biotechnology
  • bioinformatics

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.